Dapivirine

Drug Profile

Dapivirine

Alternative Names: AIDS-105293; Dapivirine gel; Dapivirine intravaginal ring; Dapivirine IVR; Dapivirine ring 004; R-147681; TMC-120

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Tibotec BVBA
  • Developer International Partnership for Microbicides; Janssen Infectious Diseases BVBA
  • Class Antivirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 14 Mar 2017 International Partnership for Microbicides and Gilead Sciences plan the REACH phase II trial for HIV infection (Prevention, In volunteers, Combination therapy) in South Africa (NCT03074786)
  • 06 Feb 2017 Suspended - Phase-I for HIV infections in USA (Rectal) (NCT03044379)
  • 01 Dec 2016 The International Partnership for Microbicides completes a phase III trial for HIV infections (Prevention) in South Africa and Uganda (NCT01539226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top